2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1469 Talazoparib-based combination therapy for cohesin-mutated MDS and AML

Charles Kinzig, MD, PhD, Caroline Conway2, Geoffrey Fell3, Zoe Reeves Evans4, Henry William Rousseau5, William Doyle6, Florence Verbeek7, Lin Han, PhD8, Jeremy Ryan9, Jessica Liegel, MD10, Andrew M Brunner, MD11, Eric Stephen Winer, MD12, Marlise Rachael Luskin, MD, MSCE13, Luca Lanino, MD14, Dylan Wilson15, Eliana Friedman16, Veronica Zehnder17, Ilene Galinsky, ANP18, Daniel J DeAngelo, MD, PhD19, Richard Stone, MD20, Zuzana Tothova, PhD, MD21, Jacqueline S. Garcia, MD22
1 Brigham & Women's Hospital, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
11 Massachusetts General Hospital, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Background.  Mutations in genes encoding members of the cohesin complex, a chromatin-associated protein complex mediating sister chromatid cohesion, transcriptional regulation, chromatin organization, and genome stability, occur in 10–20% of myeloid malignancies. Our preclinical data demonstrate that cohesin-mutated AML cells accrue DNA damage and are sensitive to the poly(ADP-ribose) polymerase inhibitor (PARPi) talazoparib. This effect can be reversed by depleting R-loops, three stranded RNA-DNA structures, using RNase H1 nuclease. In cell lines and mouse models of STAG2-mutant AML and MDS, we found that combination treatment with PARPi and hypomethylating agent (HMA) induces significantly higher genotoxic stress, apoptosis and cell killing than either agent alone, prompting clinical translation. Here, we present the results from a pilot proof-of-concept trial of talazoparib with or without decitabine in cohesin-mutated MDS and AML (NCT03974217).

Methods.  The trial enrolled at three sites. Eligible patients included those with a diagnosis of relapsed/refractory (R/R) AML, R/R MDS, or IPSS-M high/very high untreated MDS; and required ≥5% blasts and a pathogenic cohesin mutation (STAG2, SMC1A, RAD21, PDS5B, or SMC3) with ≥5% variant allele fraction (VAF). In Part 1 (safety cohort), patients received talazoparib 0.75 mg once daily as monotherapy (28-day cycles). In Part 2, patients received a 14-day talazoparib 0.75 mg monotherapy lead-in followed by combination talazoparib 0.75 mg daily and decitabine 20 mg/m2 on days 1–5 (28-day cycles). Primary endpoint was to determine the proportion of patients with ≥50% blast reduction after cycle 1. Secondary endpoints included safety, tolerability, and overall response rate (ORR) for MDS by IWG 2023 and AML by ELN 2022. DLT was defined as treatment-related death, grade ≥3 non-heme toxicity, or grade 4 ANC or platelet count ≥42 days from cycle start. R-loop burden, DNA damage, and subclonal architecture were determined via flow cytometry, immunofluorescence and scDNA-sequencing.

Results.  The study enrolled 13 patients (5 in Part 1 and 8 in Part 2) with a median age of 76 years (range, 63–81), and all but one were male. 10 patients (77%) had MDS (4 previously untreated and 6 R/R), and 3 patients (23%) had R/R AML. All 13 patients had at least 1 STAG2 mutation with a median VAF of 46.2% (range, 8.3-94.1%). 3/13 patients had additional detectable sub-clonal cohesin-mutations. Median number of prior treatment lines was 2, including 8 (62%) with prior HMA.  

Patients received a median of 2 cycles (range, 1–5). Most frequent grade ≥3 treatment-related adverse events were thrombocytopenia (46%), WBC decrease (46%), anemia (23%), self-limited GI bleeding (23%), and febrile neutropenia (8.7%). No DLTs were observed. 30-day mortality was 0% and 60-day mortality was 9% (AML-related).

11/13 (85%) patients were evaluable for the primary endpoint, including 4/5 in Part 1 and 7/8 in Part 2. Two patients were unevaluable without available follow-up due to the COVID19 pandemic and premature withdrawal. 2/11 (18% [95% CI, 2%-52%]) demonstrated ≥50% blast reduction after cycle 1, including 1 in Part 1 and 1 in Part 2. Primary endpoint was met. In Part 1 (monotherapy), 1 patient had MLFS, but no protocol-defined response was observed. In Part 2 (combination), the ORR was 57% (95% CI, 18–90%), including 3 patients with CR/CRh and complete STAG2mut molecular response, and 1 patient with CR and partial STAG2mut molecular response. 1/4 (25%) responders was refractory to prior HMA. A reduction of ≥50% in STAG2mut VAF occurred in 6/7 (86%). Median time to response was 30 days (Q1/Q3, 25.5/88.5 days, IQR=63). 

As preclinical data demonstrated R-loop dependent PARPi sensitivity, we performed correlative studies to assess on-target activity. We identified a persistent and significant reduction in nuclear and cytoplasmic R-loops in 4/4 responders, but not in non-responders, by end of Cycle 1 and/or at time of CR. Additional studies are underway in 3 PDX AML models successfully generated from trial patients to explore extent to which responses are attributable to combination therapy versus HMA alone, and dependent on R-loop formation.

Conclusion.  We demonstrate tolerability and proof-of-concept evidence of biological and preliminary clinical activity with talazoparib and decitabine combination therapy in patients with cohesin-mutated MDS/AML. We propose R-loop formation as a potential biomarker of response.

Charles Kinzig, MD, PhD: No relevant conflicts of interest to declare.